Centogene to Open New Lab for COVID-19 Testing
The lab is expected to open in April 2020 and will increase the company’s capacity for diagnostic testing of rare genetic diseases along with its COVID-19 capabilities.
Centogene, a Germany-based commercial-stage company focused on rare diseases, announced on April 15, 2020 that it will open a new laboratory in Hamburg, Germany to increase testing capacity for COVID-19.
The lab facilities and equipment were acquired from Provecs Medical, a company formerly active in cancer immunotherapy, a company press release said. The lab is expected to open in April 2020 and will increase the company’s capacity for diagnostic testing of rare genetic diseases along with its COVID-19 capabilities.
"The opening of our lab in Hamburg will significantly contribute to the scaling and success of our COVID-19 testing initiative,” said Dr. Arndt Rolfs, CEO, Centogene, in the press release. “Once we have overcome the challenges of this pandemic and returned to a sense of normalcy, we will further equip our labs in order to continue to strengthen our commitment to rare disease patients around the world â offering transformational medical solutions."
Source: Centogene
